Lund Arthritis Research Group (LARG)
61 – 70 of 89
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis : results from the SWEFOT trial population
(
- Contribution to journal › Article
-
Mark
Biological treatment of ankylosing spondylitis : A nationwide study of treatment trajectories on a patient level in clinical practice
(
- Contribution to journal › Article
-
Mark
Serum biomarkers for prediction of response to methotrexate monotherapy in early rheumatoid arthritis : Results from the SWEFOT trial
(
- Contribution to journal › Article
-
Mark
Risk factors for development and persistence of chronic widespread pain in spondyloarthritis : a population-based two-year follow-up study
(
- Contribution to journal › Article
-
Mark
Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis : Results from the SPARTAKUS cohort
(
- Contribution to journal › Article
-
Mark
Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) : A systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD
(
- Contribution to journal › Article
- 2018
-
Mark
Prevalence of chronic widespread pain in a population-based cohort of patients with spondyloarthritis : a cross-sectional study
(
- Contribution to journal › Article
-
Mark
Patient-Reported Outcomes Are More Important Than Objective Inflammatory Markers for Sick Leave in Biologics-Treated Patients With Rheumatoid Arthritis
(
- Contribution to journal › Article
-
Mark
The risk of clinically diagnosed gout by serum urate levels : Results from 30 years follow-up of the Malmö preventive project cohort in southern Sweden
(
- Contribution to journal › Article
-
Mark
Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren’s syndrome without disease modifying treatment
(
- Contribution to journal › Article